Evidence map›Paper›PMID 42369455›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Cross-Device Adaptation of Mirai for Mammography-Based Breast Cancer Risk Prediction.

Adriana Sistig, Joseph H Rothstein, Tejomay Gadgil, Ninah Achacoso, Stacey E Alexeeff, Lawrence D Gerstley, Robert J Klein, Laurie R Margolies, Albert Pu, Cara L Smith Gueye and 6 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Adriana SistigDepartment of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0211-3629
Joseph H RothsteinDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8618-1660
Tejomay GadgilDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.ORCID 0009-0005-8338-0997
Ninah AchacosoDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.ORCID 0000-0001-8988-6976
Lawrence D GerstleyDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.ORCID 0009-0009-7463-5846
Robert J KleinDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3539-5391
Laurie R MargoliesDepartment of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-7037-7570
Albert PuKaiser Permanente Information Technology, Oakland, CA, USA.
Cara L Smith GueyeDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.ORCID 0009-0006-9858-8886
Marvella VillaseñorDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Mark WestleyDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Laurel A HabelDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Vignesh A ArasuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.ORCID 0000-0003-4315-3106
Weiva SiehDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0085-1190
Li ShenDepartment of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-5190-2851

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
WISDOM: A platform to optimize subtype-specific screening and preventionP01CA281826 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFREY A TICE · 2024 to 2026
$13.5M
Radiomic and genomic predictors of breast cancer riskR01CA264987 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Vignesh A Arasu, Li Shen · 2021 to 2026
$3.5M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
AI Mount Sinai: High-performance computational and data ecosystem for biomedical discoveryS10OD038231 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2025 to 2025
$2.0M
NCATS NIH HHS UL1 TR004419NCI NIH HHS P01 CA281826NCI NIH HHS R01 CA264987NIH HHS S10 OD030463NIH HHS S10 OD038231
6 · The paper itself

Abstract

Fine-tuning can adapt pretrained medical imaging models to new clinical datasets, but device-specific domain shifts may limit generalizability. We evaluated Mirai, a mammography-based deep learning model for breast cancer risk prediction, in a large screening cohort containing Hologic and General Electric (GE) full-field digital mammography systems, including GE Premium View (GE PV) and Tissue Equalization (GE TE) post-processing software. Native Mirai showed lower performance on TE images than on Hologic or PV images. Fine-tuning on TE images improved TE performance, particularly for short-term risk prediction, but substantially reduced performance on Hologic images, consistent with catastrophic forgetting. To mitigate this effect, we developed a device-invariant model using interleaved multi-device sampling and conditional adversarial training. This approach largely restored Hologic performance while maintaining improved TE performance, providing better robustness across heterogeneous imaging platforms. Comparison of cumulative and annual risk AUCs over a five-year time horizon further showed that performance gains were driven mainly by short- and intermediate-term predictions. These findings highlight both the value and dangers of device-specific fine-tuning and support balanced domain-adaptation strategies for deploying mammography-based risk models across diverse clinical imaging environments.

Identifiers

PMID42369455
PMCPMC13308276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.